clofibrate has been researched along with Heart Disease, Ischemic in 6 studies
angiokapsul: contains clofibrate & insoitolnicotinate
| Excerpt | Relevance | Reference |
|---|---|---|
| "Clofibrate was able to decrease Angiotensin II (AngII), AngII AT1-receptor, whereas Ang-(1-7) and AngII AT2-receptor expression increased." | 5.38 | Clofibrate PPARα activation reduces oxidative stress and improves ultrastructure and ventricular hemodynamics in no-flow myocardial ischemia. ( Cervantes-Pérez, LG; Del Valle-Mondragón, L; Hong, E; Ibarra-Lara, L; Pastelín-Hernández, GS; Pérez-Severiano, F; Ramírez-Ortega, M; Sánchez-Mendoza, A; Soria-Castro, E; Torres-Narváez, JC, 2012) |
| " Male Wistar rats (weighing 300-350 g) were assigned to the following groups: (1) sham, (2) myocardial ischemia vehicle-treated (MI-V), and (3) myocardial ischemia clofibrate-treated." | 3.81 | PPARα Stimulation Modulates Myocardial Ischemia-induced Activation of Renin-Angiotensin System. ( Cervantes-Pérez, LG; del Valle-Mondragón, L; Hong, E; Ibarra-Lara, L; Pastelín-Hernández, GS; Pérez-Severiano, F; Ramírez-Ortega, M; Sánchez-Aguilar, M; Sánchez-Mendoza, A; Soria-Castro, E; Torres-Narváez, JC, 2015) |
| "Clofibrate was able to decrease Angiotensin II (AngII), AngII AT1-receptor, whereas Ang-(1-7) and AngII AT2-receptor expression increased." | 1.38 | Clofibrate PPARα activation reduces oxidative stress and improves ultrastructure and ventricular hemodynamics in no-flow myocardial ischemia. ( Cervantes-Pérez, LG; Del Valle-Mondragón, L; Hong, E; Ibarra-Lara, L; Pastelín-Hernández, GS; Pérez-Severiano, F; Ramírez-Ortega, M; Sánchez-Mendoza, A; Soria-Castro, E; Torres-Narváez, JC, 2012) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 3 (50.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (33.33) | 24.3611 |
| 2020's | 1 (16.67) | 2.80 |
| Authors | Studies |
|---|---|
| Ibarra-Lara, L | 3 |
| Sánchez-Aguilar, M | 2 |
| Del Valle-Mondragón, L | 3 |
| Soria-Castro, E | 3 |
| Cervantes-Pérez, LG | 3 |
| Pastelín-Hernández, G | 1 |
| Sánchez-Mendoza, A | 3 |
| Hong, E | 2 |
| Pérez-Severiano, F | 2 |
| Torres-Narváez, JC | 2 |
| Ramírez-Ortega, M | 2 |
| Pastelín-Hernández, GS | 2 |
| Fowler, PB | 1 |
| Heady, JA | 2 |
| Morris, JN | 2 |
| Oliver, MF | 2 |
2 trials available for clofibrate and Heart Disease, Ischemic
| Article | Year |
|---|---|
WHO clofibrate/cholesterol trial: clarifications.
Topics: Cholesterol; Clofibrate; Female; Humans; Male; Myocardial Ischemia; Thyroid Diseases; World Health O | 1993 |
WHO clofibrate/cholesterol trial: clarifications.
Topics: Clofibrate; Humans; Hypercholesterolemia; Male; Meta-Analysis as Topic; Myocardial Ischemia; Researc | 1992 |
4 other studies available for clofibrate and Heart Disease, Ischemic
| Article | Year |
|---|---|
Clofibrate improves myocardial ischemia-induced damage through regulation of renin-angiotensin system and favours a pro-vasodilator profile in left ventricle.
Topics: Angiotensin II; Animals; Clofibrate; Fibrosis; Heart Ventricles; Male; Myocardial Ischemia; Myocardi | 2020 |
PPARα Stimulation Modulates Myocardial Ischemia-induced Activation of Renin-Angiotensin System.
Topics: Angiotensin-Converting Enzyme 2; Animals; Bradykinin; Clofibrate; Disease Models, Animal; Enzyme Act | 2015 |
Clofibrate PPARα activation reduces oxidative stress and improves ultrastructure and ventricular hemodynamics in no-flow myocardial ischemia.
Topics: Animals; Antioxidants; Catalase; Clofibrate; Disease Models, Animal; Hemodynamics; Lipid Peroxidatio | 2012 |
Ischaemic heart disease and cholesterol ... and mislead on adverse effects.
Topics: Clinical Trials as Topic; Clofibrate; Humans; Male; Myocardial Ischemia | 1994 |